AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Athersys to Host Year-End 2019 Financial Results Call

February 10, 2020 GMT

CLEVELAND--(BUSINESS WIRE)--Feb 10, 2020--

Athersys, Inc. (Nasdaq: ATHX) will release its year-end 2019 financial results at approximately 4:00 PM Eastern Time on Monday, March 16, 2020, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results. Members of the management team will host the call as follows:

Date

March 16, 2020

Time

4:30 p.m. (Eastern Time)

Telephone access: US and Canada

(877) 396-3286

Telephone access: International

(647) 689-5528

Encore Passcode (needed for the replay only)

9937937

Live webcast

Webcast link

We encourage shareholders to listen using the webcast link, and to use the phone line if you intend to ask a question. A replay will be available on the webcast link at www.athersys.com under the investors section approximately three hours after the call has ended. Shareholders may also call in for on-demand listening shortly after the completion of the call until 11:59 PM Eastern Time on March 21, 2020 by dialing (800) 585-8367 or (416) 621-4642 and entering the conference code 9937937.

About Athersys

Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem ® cell therapy product, a patented, adult-derived “off-the-shelf” stem cell product, initially for disease indications in the neurological, inflammatory and immune, cardiovascular and other critical care indications and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance the MultiStem cell therapy toward commercialization. More information is available at www.athersys.com. Follow Athersys on Twitter at www.twitter.com/athersys.

View source version on businesswire.com:https://www.businesswire.com/news/home/20200210005117/en/

CONTACT: William (B.J.) Lehmann, J.D.

President and Chief Operating Officer

Tel: (216) 431-9900

bjlehmann@athersys.comKaren Hunady

Director of Corporate Communications and Investor Relations

Tel: (216) 431-9900

khunady@athersys.comDavid Schull

Russo Partners, LLC

Tel: (212) 845-4271 or (858) 717-2310

David.schull@russopartnersllc.com

KEYWORD: OHIO UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: CARDIOLOGY STEM CELLS BIOTECHNOLOGY OTHER HEALTH HEALTH GENERAL HEALTH PHARMACEUTICAL OTHER SCIENCE RESEARCH HOSPITALS SCIENCE

SOURCE: Athersys, Inc.

Copyright Business Wire 2020.

PUB: 02/10/2020 08:00 AM/DISC: 02/10/2020 08:01 AM

http://www.businesswire.com/news/home/20200210005117/en